We are live on ! Find out more
BTAI icon

BioXcel Therapeutics
BTAI

93 hedge funds and large institutions have $283M invested in BioXcel Therapeutics in 2021 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 36 increasing their positions, 23 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more call options, than puts

Call options by funds: $4.8M | Put options by funds: $2.88M

57% more repeat investments, than reductions

Existing positions increased: 36 | Existing positions reduced: 23

0.25% more ownership

Funds ownership: 2.86% → 3.11% (+0.25%)

10% less funds holding

Funds holding: 103 → 93 (-10)

27% less capital invested

Capital invested by funds: $388M → $283M (-$105M)

38% less first-time investments, than exits

New positions opened: 15 | Existing positions closed: 24

Holders
93
Holders Change
-10
Holders Change %
-9.71%
% of All Funds
1.43%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
15
Increased
36
Reduced
23
Closed
24
Calls
$4.8M
Puts
$2.88M
Net Calls
+$1.92M
Net Calls Change
+$2.22M

Top Buyers

Rank Fund Capital Flow
1
AllianceBernstein
AllianceBernstein
Tennessee
+$13.1M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$11M
3
Morgan Stanley
Morgan Stanley
New York
+$3.06M
4
Bank of America
Bank of America
North Carolina
+$2.07M
5
BlackRock
BlackRock
New York
+$1.96M

Top Sellers

Rank Fund Capital Flow
1
GCP
GSA Capital Partners
United Kingdom
-$1.8M
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$1.65M
3
B
Bailard
California
-$1.4M
4
ACM
ACT Capital Management
Pennsylvania
-$805K
5
AS
Altshuler Shaham
Israel
-$744K
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$85.3M +$11M +25,729 +11%
AllianceBernstein
2
AllianceBernstein
Tennessee
$30.7M +$13.1M +30,532 +48%
AIM
3
Artemis Investment Management
United Kingdom
$28.6M +$808K +1,883 +2%
State Street
4
State Street
Massachusetts
$27.3M +$443K +1,032 +1%
BlackRock
5
BlackRock
New York
$26.2M +$1.96M +4,557 +6%
Vanguard Group
6
Vanguard Group
Pennsylvania
$20.8M +$1.46M +3,401 +6%
Massachusetts Financial Services
7
Massachusetts Financial Services
Massachusetts
$8.43M -$81.1K -189 -0.7%
Geode Capital Management
8
Geode Capital Management
Massachusetts
$6.13M +$114K +266 +1%
Morgan Stanley
9
Morgan Stanley
New York
$4.77M +$3.06M +7,124 +94%
UBS Group
10
UBS Group
Switzerland
$4.06M -$424K -987 -7%
Northern Trust
11
Northern Trust
Illinois
$3.93M +$86.2K +201 +2%
Susquehanna International Group
12
Susquehanna International Group
Pennsylvania
$3.62M -$1.65M -3,838 -26%
Bank of America
13
Bank of America
North Carolina
$2.87M +$2.07M +4,830 +121%
Charles Schwab
14
Charles Schwab
California
$2.68M +$46.8K +109 +1%
Rafferty Asset Management
15
Rafferty Asset Management
New York
$2M +$1.04M +2,427 +65%
Citigroup
16
Citigroup
New York
$1.58M +$1.02M +2,387 +97%
BNP Paribas Financial Markets
17
BNP Paribas Financial Markets
France
$1.36M +$1.11M +2,597 +164%
N
18
Nuveen
North Carolina
$1.22M +$367K +856 +29%
Bank of New York Mellon
19
Bank of New York Mellon
New York
$1.15M +$69.1K +161 +5%
AA
20
AlphaCentric Advisors
Puerto Rico
$1.02M +$402K +937 +43%
Goldman Sachs
21
Goldman Sachs
New York
$1.01M +$369K +860 +38%
Citadel Advisors
22
Citadel Advisors
Florida
$972K +$395K +920 +44%
Swiss National Bank
23
Swiss National Bank
Switzerland
$862K – – –
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
24
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Ontario, Canada
$813K – – –
DC
25
Davenport & Co
Virginia
$705K +$325K +757 +54%
1
2 3 4 5

BTAI Hedge Fund Activity: Q4 2021 in Review

93 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in BioXcel Therapeutics (BTAI) for Q4 2021, worth a combined $283M — down 27% from $388M a quarter earlier.

Sellers outnumbered buyers: 24 funds closed out of BTAI and 15 opened new positions — a net loss of 9 holders — while 23 trimmed existing stakes and 36 added.

The largest buyer was AllianceBernstein, adding an estimated $13.1M. The largest seller was GSA Capital Partners, exiting entirely with an estimated $1.8M sold.

  • 93 institutional investors held BioXcel Therapeutics (BTAI) as of Q4 2021, down from 103 in Q3 2021.
  • Funds reported $283M of BioXcel Therapeutics stock for Q4 2021, down 27% quarter-over-quarter.
  • 15 funds opened new BioXcel Therapeutics positions in Q4 2021 and 24 closed out, a net change of -9 holders.
  • The largest BioXcel Therapeutics buyer in Q4 2021 was AllianceBernstein, an estimated $13.1M added.
  • The largest BioXcel Therapeutics seller in Q4 2021 was GSA Capital Partners, an estimated $1.8M sold.

Based on aggregated 13F filings for Q4 2021.